ZVRA — Zevra Therapeutics Share News
0.000.00%
Last trade - 00:00- $613.43m
- $391.86m
- $106.47m
Brief: Zevra Therapeutics Appoints Neil F. Mcfarlane As President, Chief Executive Officer And Director
Brief: Zevra Therapeutics Announces Interim Data From The Phase 2 Clinical Trial Of Kp1077 For Idiopathic Hypersomnia
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Zevra Therapeutics gains on upbeat Q2 results
Brief: Zevra Therapeutics Q2 revenue USD 8.47 million
Zevra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Zevra Therapeutics Reports Q2 Results
Zevra Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Zevra Therapeutics Appoints Thomas Anderson To Board Of Directors, Reports Retirement Of Matthew R. Plooster
XOMA Corp rises on acquiring assets royalty, milestone rights from LadRx
Brief: Zevra Therapeutics Reports First Quarter 2023 Results
Zevra Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Zevra Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tyson Foods, Estee Lauder, Energy stocks
Zevra Therapeutics falls after CEO resignation
Brief: Zevra Announces Board Of Directors And Leadership Changes
Zevra Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview